Erythropoietin Stimulating Agents Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Erythropoietin Stimulating Agents Market Analysis
The erythropoietin stimulating agents (ESAs) market was valued at approximately USD 8,223 million in 2020 and is expected to witness a revenue of USD 13,436 million in 2026, with a CAGR of 8.6% over the forecast period.
According to a research study published in the American Journal of Kidney Disease, 2020, among the patients with COVID-19, with or without Acute Kidney Injury(AKI) and anemia, ESAs should be avoided in the therapy, as these patients are unlikely to mount an effective response to ESAs due to the inflammation. Thus, the risks associated with ESA treatments are expected to outweigh the potential benefits. Hence, the COVID-19 pandemic is expected to severely impact the studied market growth during the pandemic.
The ESAs market is driven by an increasing number of patients suffering from anemia, increasing applications in HIV infections and end-stage renal disorder, risks of thrombosis during surgeries, and pure red cell aplasia.
Anemia has been one of the serious nutrition-related diseases over the past few decades and is the major reason for increased morbidity and mortality, especially in low and middle-income countries. According to a research article published in PLoS One, 2019, Anemia is estimated to affect nearly 1.62 billion people worldwide and the prevalence of anemia was found to be 41.1% in Ethiopia. Additionally, as per the Lancet Global Health, 2019, India is estimated to account for nearly one-quarter of the global anemia cases. Iron Deficiency Anemia is common in children and women and is associated with sensory, motor, cognitive, language, and socioemotional deficits. Hence, the early detection and initiation of effective treatment strategies in the early stages of anemia are very important, especially among infants.
Other causes of anemia include parasite infections, such as ascaris, schistosomiasis, and hookworms, which can lower the hemoglobin (Hb) concentration in blood, along with heavy blood loss during menstruation among women.
Additionally, as per the Centers for Disease Control and Prevention's (CDC) 2019 report, it was estimated that about 37 million (15%) of the adult population in the United States had chronic kidney disease (CKD), which increases the severity of anemia. Therefore, as the number of people affected by anemia increases, the demand for erythropoietin stimulating agents (which aid in stimulating the production of more red blood cells) also increases. Hence, the aforementioned factors are expected to boost market growth over the forecast period. However, stringent regulatory guidelines to obtain product approvals and the adverse side effects of ESAs are expected to hamper the market growth.
Erythropoietin Stimulating Agents Market Trends
This section covers the major market trends shaping the Erythropoietin Stimulating Agents Market according to our research experts:
Cancer Application Expected to Dominate the Market Over the Forecast Period
Anemia is observed among the majority of patients undergoing cancer treatment, which is expected to drive this segment's growth over the forecast period. The severity of the disease among patients depends on the type of chemotherapy used, type and stage of neoplasia, and patient characteristics. Severe anemia, particularly among children and the elderly, can lead to fatigue, weakness, and depression, which severely reduce the quality of life for cancer patients.
Besides, anemia impairs the efficacy of cancer therapies. Several research studies and clinical trials have revealed that treating anemia that is associated with various cancers with erythropoietin can improve the clinical outcome of these patients. Erythropoietin acts against two main causes of anemia in cancer patients undergoing chemotherapy, i.e., against myelosuppression and endogenous erythropoietin deficiency. Patients diagnosed with anemia associated with cancer are most likely to be prescribed with erythropoietin in the form of epoetin alfa and epoetin beta. The most prescribed products include Procrit, Epogen, and NeoRecormon.
As per a research article published in the Lancet, 2020, there was no direct co-relation found to state that the cancer patients on cytotoxic chemotherapy or other anticancer treatment possess higher chances of mortality from COVID-19 as compared with those not on active treatment. Hence, COVID-19 is expected to not impact the mortality rate of cancer patients on chemotherapy, which in turn may not impair the segment growth during the pandemic. However, due to the temporary postponement of elective surgeries during COVID-19, cancer treatments are reduced to some extent.
As per Globocan 2020, the incidence of new cancer cases was estimated to be 19,292,789 in 2020, with nearly 9,958,133 deaths due to cancers globally. Additionally, the new cancer incidence is estimated to reach 30.2 million by 2040 as per International Agency for Research on Cancer (IARC) worldwide. As the rapidly dividing cancer cells consume a large amount of iron for their DNA replication, growth, and metastatic process, cancer patients are always diagnosed with severe anemia. Hence, with the increase in the number of cancer patients and chemotherapy procedures, the erythropoietin stimulating agents market is expected to grow during the forecast period.
North America is Expected to Hold the Largest Market Share over the Forecast Period
The market for erythropoietin stimulating agents in North America is estimated to hold the largest share on account of the high occurrence of various disorders that eventually cause anemia in the region.
According to the American Society of Hematology, 2020, patients receiving active treatment for aplastic anemia may experience immunosuppression, which increases the risk of infection from COVID-19 and associated complications during the pandemic. Additionally, hospitalization of patients for anti-thymocyte globulin (ATG) administration for aplastic anemia treatment may be problematic given the lack of bed availability and risk of exposure to COVID-19 patients. Hence, the pandemic situation is expected to impact the treatment procedures for anemia, which in turn affects this regional market's growth.
ESAs have been effectively used in the treatments for various chronic diseases, like chronic kidney disease (CKD), cancer, neural, and HIV infections. Adults with diabetes or high blood pressure are prone to CKD. According to the Centers for Disease Control and Prevention's (CDC), the National Diabetes Statistics Report, 2020, 34.2 million people of all ages, accounting for 10.5% of the American population, had diabetes in 2018. Hence with the increasing number of people at high risk for CKD, the market for ESAs is expected to witness substantial growth in this region.
In the North American region, the United States holds the largest market share. According to the GLOBOCON 2020, the new cancer cases diagnosed were 2,281,658 in the United States in 2020, with 612,390 deaths. Among all cancers, breast cancer had the highest incidence rate with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809), in 2020 in the United States. The high incidence of cancers leads to the demand for ESAs, to minimize anemic conditions in target patients, which in turn is expected to boost the market growth in the region over the forecast period.
Erythropoietin Stimulating Agents Industry Overview
The ESAs market is highly competitive, and it includes global and local companies. Some of the key players in the market are Amgen, Thermo Fisher Scientific, Johnson and Johnson, F. Hoffmann La Roche, and Pfizer Inc. Numerous pharmaceutical manufacturers are taking initiatives to develop and produce ESAs after the expiration of patents and are evolving various strategic alliances, such as acquisitions and collaborations, to expand the product portfolio globally.
Erythropoietin Stimulating Agents Market Leaders
-
Amgen Inc.
-
F. Hoffmann La Roche Ltd
-
Thermo Fisher Scientific
-
Johnson and Johnson
-
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order
Erythropoietin Stimulating Agents Market News
In July 2020, a Phase III clinical trial of Efepoetin Alfa for the treatment of anemia associated with chronic kidney disease patients, who are not on dialysis, was initiated by PT Kalbe Genexine Biologics.
In February 2020, Samsung Medical Center initiated a Phase III clinical trial of the multicenter randomized study on the efficacy of intravenous iron injection, Ferinject, in cancer patients with anemia.
Erythropoietin Stimulating Agents Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Disease Burden of Anemia
- 4.2.2 Rising Applications in HIV Infections and End-stage Renal Disorder
- 4.2.3 Risks of Thrombosis, during Surgeries, and Pure Red Cell Aplasia
-
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Guidelines
- 4.3.2 Adverse Side Effects
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Type
- 5.1.1 Epoetin Alfa
- 5.1.2 Epoetin Beta
- 5.1.3 Darbepoetin Alfa
- 5.1.4 Other Types
-
5.2 By Application
- 5.2.1 Cancer
- 5.2.2 Renal Disorders
- 5.2.3 Anti-retroviral Treatment
- 5.2.4 Neural Diseases
- 5.2.5 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States (By Type and By Application)
- 5.3.1.2 Canada (By Type and By Application)
- 5.3.1.3 Mexico (By Type and By Application)
- 5.3.2 Europe
- 5.3.2.1 Germany (By Type and By Application)
- 5.3.2.2 United Kingdom (By Type and By Application)
- 5.3.2.3 France (By Type and By Application)
- 5.3.2.4 Italy (By Type and By Application)
- 5.3.2.5 Spain (By Type and By Application)
- 5.3.2.6 Rest of Europe (By Type and By Application)
- 5.3.3 Asia-Pacific
- 5.3.3.1 China (By Type and By Application)
- 5.3.3.2 Japan (By Type and By Application)
- 5.3.3.3 India (By Type and By Application)
- 5.3.3.4 Australia (By Type and By Application)
- 5.3.3.5 South Korea (By Type and By Application)
- 5.3.3.6 Rest of Asia-Pacific (By Type and By Application)
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC (By Type and By Application)
- 5.3.4.2 South Africa (By Type and By Application)
- 5.3.4.3 Rest of Middle East and Africa (By Type and By Application)
- 5.3.5 South America
- 5.3.5.1 Brazil (By Type and By Application)
- 5.3.5.2 Argentina (By Type and By Application)
- 5.3.5.3 Rest of South America (By Type and By Application)
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Amgen Inc.
- 6.1.2 BioSidus
- 6.1.3 Biocon Limited
- 6.1.4 Celltrion Inc.
- 6.1.5 F. Hoffmann-La Roche Ltd
- 6.1.6 Intas Pharmaceuticals Ltd
- 6.1.7 Johnson and Johnson
- 6.1.8 Pfizer Inc.
- 6.1.9 Teva Pharmaceutical Industries Ltd
- 6.1.10 Thermo Fisher Scientific
- 6.1.11 LG Lifesciences, Ltd
- 6.1.12 Ranbaxy Laboratories Ltd
- 6.1.13 Sun Pharmaceutical Industries Ltd
- 6.1.14 Dr. Reddy's Laboratories Ltd
- 6.1.15 Celon Laboratories Pvt Ltd
- 6.1.16 Lupin Pharma
- 6.1.17 Nanogen Pharmaceutical Biotechnology
- 6.1.18 Novartis AG(Sandoz)
- 6.1.19 Probiomed S.A. de C.V.
- 6.1.20 Panacea Biotec Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityErythropoietin Stimulating Agents Industry Segmentation
As per the scope of the report, ESAs are similar to erythropoietin, as they stimulate the growth of red blood cells. ESAs have been approved for the treatment of anemia due to chronic kidney failure, chemotherapy, and HIV, and for the treatment of reduced red blood cells during critical surgical procedures. The erythropoietin stimulating agents market is segmented by type, application, and geography. By type, the market is segmented into epoetin alfa, epoetin beta, darbepoetin alfa, and other types. By application, the market is segmented into cancer, renal disorders, anti-retroviral treatment, neural diseases, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD million) for the above segments.
| By Type | Epoetin Alfa | |
| Epoetin Beta | ||
| Darbepoetin Alfa | ||
| Other Types | ||
| By Application | Cancer | |
| Renal Disorders | ||
| Anti-retroviral Treatment | ||
| Neural Diseases | ||
| Other Applications | ||
| Geography | North America | United States (By Type and By Application) |
| Canada (By Type and By Application) | ||
| Mexico (By Type and By Application) | ||
| Geography | Europe | Germany (By Type and By Application) |
| United Kingdom (By Type and By Application) | ||
| France (By Type and By Application) | ||
| Italy (By Type and By Application) | ||
| Spain (By Type and By Application) | ||
| Rest of Europe (By Type and By Application) | ||
| Geography | Asia-Pacific | China (By Type and By Application) |
| Japan (By Type and By Application) | ||
| India (By Type and By Application) | ||
| Australia (By Type and By Application) | ||
| South Korea (By Type and By Application) | ||
| Rest of Asia-Pacific (By Type and By Application) | ||
| Geography | Middle East and Africa | GCC (By Type and By Application) |
| South Africa (By Type and By Application) | ||
| Rest of Middle East and Africa (By Type and By Application) | ||
| Geography | South America | Brazil (By Type and By Application) |
| Argentina (By Type and By Application) | ||
| Rest of South America (By Type and By Application) |
Erythropoietin Stimulating Agents Market Research FAQs
What is the current Global Erythropoietin Stimulating Agents Market size?
The Global Erythropoietin Stimulating Agents Market is projected to register a CAGR of 8.60% during the forecast period (2024-2029)
Who are the key players in Global Erythropoietin Stimulating Agents Market?
Amgen Inc., F. Hoffmann La Roche Ltd, Thermo Fisher Scientific, Johnson and Johnson and Pfizer Inc. are the major companies operating in the Global Erythropoietin Stimulating Agents Market.
Which is the fastest growing region in Global Erythropoietin Stimulating Agents Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Erythropoietin Stimulating Agents Market?
In 2024, the North America accounts for the largest market share in Global Erythropoietin Stimulating Agents Market.
What years does this Global Erythropoietin Stimulating Agents Market cover?
The report covers the Global Erythropoietin Stimulating Agents Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Erythropoietin Stimulating Agents Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Erythropoietin Stimulating Agents Industry Report
Statistics for the 2024 Erythropoietin Stimulating Agents market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Erythropoietin Stimulating Agents analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
